Giving patients a chance is what drives us. We are committed to developing safe and effective therapies for those suffering of a wide range of fibrotic diseases.
Pliant is currently targeting fibrotic diseases in a variety of organs and conditions, including the lung (IPF), liver (primary sclerosing cholangitis, NASH and cirrhosis), kidney (renal fibrosis), skin (scleroderma) and the gastrointestinal tract (stricturing Crohn’s disease).
We are eager to initiate clinical development of our lead product candidate, PLN-74809, in early 2019 as a potential treatment option for patients with IPF.
IPF is a chronic and progressive fibrotic disease in which lung tissue becomes thickened, stiff and scarred, leading to increased difficulty in breathing and decreased quality of life. As lung fibrosis progresses, it becomes increasingly difficult for the lungs to transfer oxygen into the bloodstream— ultimately preventing vital organs from receiving the oxygen necessary to function properly. IPF currently affects approximately 140,000 people in the U.S.
If you are interested in learning more about this clinical trial, email us at info@pliantrx.com.
IPF currently affects approximately
people in the U.S.
The following is a representation of organizations that offer resources and information on fibrotic disease and clinical trials:
Pliant Therapeutics, Inc.
260 Littlefield Avenue,
South San Francisco, CA 94080
info@pliantrx.com
650.481.6770